eShowcase: iPlan Flow
Software disentangles delivery efficacy from drug efficacy, improving trial results
Software disentangles delivery efficacy from drug efficacy, improving trial results
BrainLab AG (Chicago, IL) has developed a system that allows targeted drug delivery into the brain for treating tumors, a technology that the company says could improve the results of drug trials and ultimately enhance the chances of regulatory approval during trials.
iPlan Flow
iPlan Flow addresses a difficult challenge, since the tight coating of blood vessels protects the brain and prevents fluids from entering it. Delivering enough drug concentration to specific brain cells is therefore problematic due to varying fluid dynamics. The technology uses magnetic resonance imaging to develop a three-dimensional image of the patient's brain. Then, it calculates the drug's distribution patterns, enabling a surgeon to identify the proper locations to place fluid delivery catheters. Potential applications include chemotherapy, gene therapy, molecular-targeted therapy, immunotherapy, and radio-immunotherapy.
BrainLab AG, (800) 784-7700, www.brainlab.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
